WO2023201358A3 - Neurotoxin compositions for use in regulating brain temperature - Google Patents
Neurotoxin compositions for use in regulating brain temperature Download PDFInfo
- Publication number
- WO2023201358A3 WO2023201358A3 PCT/US2023/065808 US2023065808W WO2023201358A3 WO 2023201358 A3 WO2023201358 A3 WO 2023201358A3 US 2023065808 W US2023065808 W US 2023065808W WO 2023201358 A3 WO2023201358 A3 WO 2023201358A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brain temperature
- neurotoxin compositions
- regulating brain
- compositions
- regulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed herein are compositions and methods for use in altering brain temperature and regulating sympathetic signaling.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331596P | 2022-04-15 | 2022-04-15 | |
| US63/331,596 | 2022-04-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023201358A2 WO2023201358A2 (en) | 2023-10-19 |
| WO2023201358A3 true WO2023201358A3 (en) | 2023-11-30 |
Family
ID=88330419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/065808 Ceased WO2023201358A2 (en) | 2022-04-15 | 2023-04-14 | Neurotoxin compositions for use in regulating brain temperature |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023201358A2 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020111657A1 (en) * | 2001-02-15 | 2002-08-15 | Dae Michael W. | Method of controlling body temperature while reducing shivering |
| US20060052854A1 (en) * | 2000-06-05 | 2006-03-09 | Mats Allers | Cerebral temperature control |
| US20130005744A1 (en) * | 2010-03-04 | 2013-01-03 | Scott Wolkenberg | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| WO2021041982A1 (en) * | 2019-08-30 | 2021-03-04 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating neurologic and psychiatric disorders |
| US20210060144A1 (en) * | 2019-08-30 | 2021-03-04 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating headache |
| US20210162024A1 (en) * | 2012-01-03 | 2021-06-03 | Curemark, Llc | Methods of treating behavioral symptoms of neurological and mental disorders |
| WO2021183962A1 (en) * | 2020-03-12 | 2021-09-16 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating cardiovascular disorders |
-
2023
- 2023-04-14 WO PCT/US2023/065808 patent/WO2023201358A2/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060052854A1 (en) * | 2000-06-05 | 2006-03-09 | Mats Allers | Cerebral temperature control |
| US20020111657A1 (en) * | 2001-02-15 | 2002-08-15 | Dae Michael W. | Method of controlling body temperature while reducing shivering |
| US20130005744A1 (en) * | 2010-03-04 | 2013-01-03 | Scott Wolkenberg | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| US20210162024A1 (en) * | 2012-01-03 | 2021-06-03 | Curemark, Llc | Methods of treating behavioral symptoms of neurological and mental disorders |
| WO2021041982A1 (en) * | 2019-08-30 | 2021-03-04 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating neurologic and psychiatric disorders |
| US20210060144A1 (en) * | 2019-08-30 | 2021-03-04 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating headache |
| WO2021183962A1 (en) * | 2020-03-12 | 2021-09-16 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating cardiovascular disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023201358A2 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004102A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND METHODS OF USE THEREOF. | |
| MY209471A (en) | Interleukin-2 agents and uses thereof | |
| WO2017210545A8 (en) | Potassium channel modulators | |
| MX2022011550A (en) | Compositions and methods for inhibiting angptl3 expression. | |
| WO2021081292A8 (en) | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS | |
| WO2022031847A3 (en) | Compositions and methods for inhibiting plp1 expression | |
| MX2023008598A (en) | Interleukin-2 mutants and uses thereof. | |
| WO2022218941A3 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
| EP4090736A4 (en) | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency | |
| WO2023201358A3 (en) | Neurotoxin compositions for use in regulating brain temperature | |
| PH12021550488A1 (en) | Thermally treated composition comprising plant proteins and methods of production and use thereof | |
| MX2023006599A (en) | Methods of using interleukin-2 agents. | |
| CA3139561A1 (en) | Progranulin modulators and methods of using the same | |
| MX2020011343A (en) | Yoghurt snack. | |
| ZA202304463B (en) | Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles | |
| WO2018213813A3 (en) | Psychotropic agents and uses thereof | |
| WO2024191937A3 (en) | Compositions and methods for treating, ameliorating, and/or preventing diseases and/or disorders | |
| MX2024015763A (en) | Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression | |
| WO2021041324A3 (en) | Compositions and methods for the treatment of pathological pain and itch | |
| MX2022002367A (en) | Neurotoxin compositions for use in treating neurologic and psychiatric disorders. | |
| WO2024168241A3 (en) | Stabilized fgf23 fusion proteins, compositions and a targeted therapy for hyperphosphatemia | |
| WO2023039270A3 (en) | Bioactive-containing granules | |
| WO2014006613A3 (en) | Plasminogen activator mutants as anti-fibrinolytic agents | |
| WO2022221559A3 (en) | Ceramide and sphingomyelin in neurological disorders | |
| WO2022261481A3 (en) | Methods and compositions for modulating sting signaling and innate immune responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23789196 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 23789196 Country of ref document: EP Kind code of ref document: A2 |